BEDFORD, Mass., Oct. 20, 2016 -- ConforMIS, Inc. (NASDAQ:CFMS) announced today that it will host a conference call on Thursday, November 3, 2016, at 4:30 p.m. Eastern Time to discuss its financial results for the third quarter 2016. To participate in the conference call, please call 877-809-6331 (or 615-247-0224 for international) and use conference ID number 5481072.
The conference call will be hosted by Philipp Lang, MD, MBA, President and Chief Executive Officer, and Paul Weiner, Chief Financial Officer. The company will issue a news release announcing its third quarter 2016 financial results on Thursday, November 3, 2016, prior to the conference call.
A live webcast of the conference call will also be available in the investor relations section of the company’s website at ir.conformis.com. The online archive of the webcast will be available on the company’s website for 30 days.
About ConforMIS, Inc.
ConforMIS is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient’s unique anatomy. ConforMIS offers a broad line of customized knee implants and pre-sterilized, single-use instruments delivered in a single package to the hospital. In recent clinical studies, ConforMIS iTotal CR demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. ConforMIS owns or exclusively in-licenses approximately 500 issued patents and pending patent applications that cover customized implants and patient-specific instrumentation for all major joints.
For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com/.
Contacts Investor Contact: Oksana Bradley [email protected] (781) 374-5598


Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 



